Molecular therapies in hepatocellular carcinoma: What can we target?

Roberto Galuppo; Dinesh Ramaiah; Oscar Moreno Ponte; Roberto Gedaly

doi:10.1007/s10620-014-3058-x

Molecular therapies in hepatocellular carcinoma: What can we target?

Roberto Galuppo, Dinesh Ramaiah, Oscar Moreno Ponte, Roberto Gedaly

Research output: Contribution to journal › Review article › peer-review

42 Scopus citations

Abstract

Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.

Original language	English
Pages (from-to)	1688-1697
Number of pages	10
Journal	Digestive Diseases and Sciences
Volume	59
Issue number	8
DOIs	https://doi.org/10.1007/s10620-014-3058-x
State	Published - Aug 2014

Bibliographical note

Funding Information:
Acknowledgments The project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Keywords

Epidermal growth factor
Hepatocellular carcinoma
Liver cancer stem cells
Ras/Raf/MAPK
Sorafenib

ASJC Scopus subject areas

Physiology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10620-014-3058-x

Cite this

@article{218b21ad2a3c4e7aa721d20171cf7641,

title = "Molecular therapies in hepatocellular carcinoma: What can we target?",

abstract = "Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.",

keywords = "Epidermal growth factor, Hepatocellular carcinoma, Liver cancer stem cells, Ras/Raf/MAPK, Sorafenib",

author = "Roberto Galuppo and Dinesh Ramaiah and Ponte, {Oscar Moreno} and Roberto Gedaly",

note = "Funding Information: Acknowledgments The project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.",

year = "2014",

month = aug,

doi = "10.1007/s10620-014-3058-x",

language = "English",

volume = "59",

pages = "1688--1697",

number = "8",

}

TY - JOUR

T1 - Molecular therapies in hepatocellular carcinoma

T2 - What can we target?

AU - Galuppo, Roberto

AU - Ramaiah, Dinesh

AU - Ponte, Oscar Moreno

AU - Gedaly, Roberto

N1 - Funding Information: Acknowledgments The project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

PY - 2014/8

Y1 - 2014/8

N2 - Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.

AB - Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.

KW - Epidermal growth factor

KW - Hepatocellular carcinoma

KW - Liver cancer stem cells

KW - Ras/Raf/MAPK

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84905571686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905571686&partnerID=8YFLogxK

U2 - 10.1007/s10620-014-3058-x

DO - 10.1007/s10620-014-3058-x

M3 - Review article

C2 - 24573715

AN - SCOPUS:84905571686

SN - 0163-2116

VL - 59

SP - 1688

EP - 1697

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

IS - 8

ER -

Molecular therapies in hepatocellular carcinoma: What can we target?

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this